Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $29 from $30 and keeps an Overweight rating on the shares. While there are not a ton of clinical catalysts in 2026, the firm thinks shares remain undervalued. Wells believes the setup will improve in the second half of 2026 ahead of several key catalysts in 2027 that could have the stock materially higher.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler
- Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
- Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
- Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)
- Nurix Therapeutics Outlines 2026 Goals and Pipeline Progress